Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

The importance of developing therapies targeting the biological spectrum of metastatic disease.

Zijlstra A, Von Lersner A, Yu D, Borrello L, Oudin M, Kang Y, Sahai E, Fingleton B, Stein U, Cox TR, Price JT, Kato Y, Welm AL, Aguirre-Ghiso JA; Board Members of the Metastasis Research Society.

Clin Exp Metastasis. 2019 Aug;36(4):305-309. doi: 10.1007/s10585-019-09972-3. Epub 2019 May 17.

PMID:
31102066
2.

Non-canonical roles for metabolic enzymes and intermediates in malignant progression and metastasis.

Williams D, Fingleton B.

Clin Exp Metastasis. 2019 Jun;36(3):211-224. doi: 10.1007/s10585-019-09967-0. Epub 2019 May 9. Review.

PMID:
31073762
3.

Blood vessel epicardial substance (BVES) reduces LRP6 receptor and cytoplasmic -catenin levels to modulate Wnt signaling and intestinal homeostasis.

Thompson JJ, Short SP, Parang B, Brown RE, Li C, Ng VH, Saito-Diaz K, Choksi YA, Washington MK, Smith JJ, Fingleton B, Brand T, Lee E, Coffey RJ, Williams CS.

Carcinogenesis. 2019 Jan 23. doi: 10.1093/carcin/bgz007. [Epub ahead of print]

PMID:
30689807
4.

Perspective on the interpretation of research and translation to clinical care with therapy-associated metastatic breast cancer progression as an example.

Fingleton B, Lange K, Caldwell B, Bankaitis KV; Board of the Metastasis Research Society.

Clin Exp Metastasis. 2017 Dec;34(8):443-447. doi: 10.1007/s10585-017-9872-8. Epub 2018 Feb 26.

PMID:
29484519
5.

Making Cancer Quiescent: SPDEF De-Cycles Beta-Catenin.

Fingleton B.

Gastroenterology. 2017 Jul;153(1):10-12. doi: 10.1053/j.gastro.2017.05.041. Epub 2017 May 29. No abstract available.

PMID:
28572010
6.

Matrix metalloproteinases as regulators of inflammatory processes.

Fingleton B.

Biochim Biophys Acta Mol Cell Res. 2017 Nov;1864(11 Pt A):2036-2042. doi: 10.1016/j.bbamcr.2017.05.010. Epub 2017 May 11. Review.

7.

Meeting report: Metastasis Research Society-Chinese Tumor Metastasis Society joint conference on metastasis.

Bankaitis K, Borriello L, Cox T, Lynch C, Zijlstra A, Fingleton B, Gužvić M, Anderson R, Neman J.

Clin Exp Metastasis. 2017 Apr;34(3-4):203-213. doi: 10.1007/s10585-017-9842-1. Epub 2017 Mar 4.

PMID:
28260197
8.

Targeting IL4/IL4R for the treatment of epithelial cancer metastasis.

Bankaitis KV, Fingleton B.

Clin Exp Metastasis. 2015 Dec;32(8):847-56. doi: 10.1007/s10585-015-9747-9. Epub 2015 Sep 18. Review.

9.

Selenoprotein P influences colitis-induced tumorigenesis by mediating stemness and oxidative damage.

Barrett CW, Reddy VK, Short SP, Motley AK, Lintel MK, Bradley AM, Freeman T, Vallance J, Ning W, Parang B, Poindexter SV, Fingleton B, Chen X, Washington MK, Wilson KT, Shroyer NF, Hill KE, Burk RF, Williams CS.

J Clin Invest. 2015 Jul 1;125(7):2646-60. doi: 10.1172/JCI76099. Epub 2015 Jun 8.

10.

Lessons from immunology: IL4R directly promotes mammary tumor metastasis.

Venmar KT, Fingleton B.

Oncoimmunology. 2014 Dec 13;3(9):e955373. eCollection 2014 Oct.

11.

Host and tumor derived MMP13 regulate extravasation and establishment of colorectal metastases in the liver.

Mendonsa AM, VanSaun MN, Ustione A, Piston DW, Fingleton BM, Gorden DL.

Mol Cancer. 2015 Feb 22;14:49. doi: 10.1186/s12943-014-0282-0.

12.

IL4 receptor α mediates enhanced glucose and glutamine metabolism to support breast cancer growth.

Venmar KT, Kimmel DW, Cliffel DE, Fingleton B.

Biochim Biophys Acta. 2015 May;1853(5):1219-28. doi: 10.1016/j.bbamcr.2015.02.020. Epub 2015 Mar 4.

13.

Interleukin-5 facilitates lung metastasis by modulating the immune microenvironment.

Zaynagetdinov R, Sherrill TP, Gleaves LA, McLoed AG, Saxon JA, Habermann AC, Connelly L, Dulek D, Peebles RS Jr, Fingleton B, Yull FE, Stathopoulos GT, Blackwell TS.

Cancer Res. 2015 Apr 15;75(8):1624-1634. doi: 10.1158/0008-5472.CAN-14-2379. Epub 2015 Feb 17.

14.

Moving targets: Emerging roles for MMPs in cancer progression and metastasis.

Shay G, Lynch CC, Fingleton B.

Matrix Biol. 2015 May-Jul;44-46:200-6. doi: 10.1016/j.matbio.2015.01.019. Epub 2015 Jan 31. Review.

15.

Stromal matrix metalloproteinase 2 regulates collagen expression and promotes the outgrowth of experimental metastases.

Bates AL, Pickup MW, Hallett MA, Dozier EA, Thomas S, Fingleton B.

J Pathol. 2015 Apr;235(5):773-83. doi: 10.1002/path.4493. Epub 2015 Jan 5.

16.

IL4 receptor ILR4α regulates metastatic colonization by mammary tumors through multiple signaling pathways.

Venmar KT, Carter KJ, Hwang DG, Dozier EA, Fingleton B.

Cancer Res. 2014 Aug 15;74(16):4329-40. doi: 10.1158/0008-5472.CAN-14-0093. Epub 2014 Jun 19.

17.

Macrophages promote progression of spasmolytic polypeptide-expressing metaplasia after acute loss of parietal cells.

Petersen CP, Weis VG, Nam KT, Sousa JF, Fingleton B, Goldenring JR.

Gastroenterology. 2014 Jun;146(7):1727-38.e8. doi: 10.1053/j.gastro.2014.02.007. Epub 2014 Feb 15.

18.

Targeting the Wnt pathway in synovial sarcoma models.

Barham W, Frump AL, Sherrill TP, Garcia CB, Saito-Diaz K, VanSaun MN, Fingleton B, Gleaves L, Orton D, Capecchi MR, Blackwell TS, Lee E, Yull F, Eid JE.

Cancer Discov. 2013 Nov;3(11):1286-301. doi: 10.1158/2159-8290.CD-13-0138. Epub 2013 Aug 6.

19.

Dietary selenium deficiency exacerbates DSS-induced epithelial injury and AOM/DSS-induced tumorigenesis.

Barrett CW, Singh K, Motley AK, Lintel MK, Matafonova E, Bradley AM, Ning W, Poindexter SV, Parang B, Reddy VK, Chaturvedi R, Fingleton BM, Washington MK, Wilson KT, Davies SS, Hill KE, Burk RF, Williams CS.

PLoS One. 2013 Jul 4;8(7):e67845. doi: 10.1371/journal.pone.0067845. Print 2013.

20.

Systems-level analysis of proteolytic events in increased vascular permeability and complement activation in skin inflammation.

auf dem Keller U, Prudova A, Eckhard U, Fingleton B, Overall CM.

Sci Signal. 2013 Jan 15;6(258):rs2. doi: 10.1126/scisignal.2003512.

21.

Kaiso directs the transcriptional corepressor MTG16 to the Kaiso binding site in target promoters.

Barrett CW, Smith JJ, Lu LC, Markham N, Stengel KR, Short SP, Zhang B, Hunt AA, Fingleton BM, Carnahan RH, Engel ME, Chen X, Beauchamp RD, Wilson KT, Hiebert SW, Reynolds AB, Williams CS.

PLoS One. 2012;7(12):e51205. doi: 10.1371/journal.pone.0051205. Epub 2012 Dec 12.

22.

Cytokine stimulation of epithelial cancer cells: the similar and divergent functions of IL-4 and IL-13.

Hallett MA, Venmar KT, Fingleton B.

Cancer Res. 2012 Dec 15;72(24):6338-43. doi: 10.1158/0008-5472.CAN-12-3544. Epub 2012 Dec 7. Review.

23.

Lack of MMP10 exacerbates experimental colitis and promotes development of inflammation-associated colonic dysplasia.

Koller FL, Dozier EA, Nam KT, Swee M, Birkland TP, Parks WC, Fingleton B.

Lab Invest. 2012 Dec;92(12):1749-59. doi: 10.1038/labinvest.2012.141. Epub 2012 Oct 8.

24.

An osteoblast-derived proteinase controls tumor cell survival via TGF-beta activation in the bone microenvironment.

Thiolloy S, Edwards JR, Fingleton B, Rifkin DB, Matrisian LM, Lynch CC.

PLoS One. 2012;7(1):e29862. doi: 10.1371/journal.pone.0029862. Epub 2012 Jan 4.

25.

Epithelial nuclear factor-κB signaling promotes lung carcinogenesis via recruitment of regulatory T lymphocytes.

Zaynagetdinov R, Stathopoulos GT, Sherrill TP, Cheng DS, McLoed AG, Ausborn JA, Polosukhin VV, Connelly L, Zhou W, Fingleton B, Peebles RS, Prince LS, Yull FE, Blackwell TS.

Oncogene. 2012 Jun 28;31(26):3164-76. doi: 10.1038/onc.2011.480. Epub 2011 Oct 17.

26.

MTGR1 is required for tumorigenesis in the murine AOM/DSS colitis-associated carcinoma model.

Barrett CW, Fingleton B, Williams A, Ning W, Fischer MA, Washington MK, Chaturvedi R, Wilson KT, Hiebert SW, Williams CS.

Cancer Res. 2011 Feb 15;71(4):1302-12. doi: 10.1158/0008-5472.CAN-10-3317. Epub 2011 Feb 8.

27.

Phase II AIDS Malignancy Consortium trial of topical halofuginone in AIDS-related Kaposi sarcoma.

Koon HB, Fingleton B, Lee JY, Geyer JT, Cesarman E, Parise RA, Egorin MJ, Dezube BJ, Aboulafia D, Krown SE.

J Acquir Immune Defic Syndr. 2011 Jan 1;56(1):64-8. doi: 10.1097/QAI.0b013e3181fc0141.

28.

Cleavage of E-Cadherin by Matrix Metalloproteinase-7 Promotes Cellular Proliferation in Nontransformed Cell Lines via Activation of RhoA.

Lynch CC, Vargo-Gogola T, Matrisian LM, Fingleton B.

J Oncol. 2010;2010:530745. doi: 10.1155/2010/530745. Epub 2010 Jun 10.

29.

Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion.

Stathopoulos GT, Sherrill TP, Karabela SP, Goleniewska K, Kalomenidis I, Roussos C, Fingleton B, Yull FE, Peebles RS Jr, Blackwell TS.

Am J Respir Crit Care Med. 2010 Nov 15;182(10):1273-81. doi: 10.1164/rccm.201001-0001OC. Epub 2010 Jul 1.

30.

Epithelial interleukin-4 receptor expression promotes colon tumor growth.

Koller FL, Hwang DG, Dozier EA, Fingleton B.

Carcinogenesis. 2010 Jun;31(6):1010-7. doi: 10.1093/carcin/bgq044. Epub 2010 Feb 22.

31.

A new dress code for MMPs: cleavage optional.

Fingleton B, Lynch CC.

Dev Cell. 2010 Jan 19;18(1):3-4. doi: 10.1016/j.devcel.2010.01.003.

32.

Inflammatory proteinase slips into tumor cells.

Fingleton B.

Nat Med. 2010 Feb;16(2):161-3. doi: 10.1038/nm0210-161. No abstract available.

PMID:
20134467
33.

Matrix metalloproteinase-7 and premalignant host responses in Helicobacter pylori-infected mice.

Ogden SR, Noto JM, Allen SS, Patel DA, Romero-Gallo J, Washington MK, Fingleton B, Israel DA, Lewis ND, Wilson KT, Chaturvedi R, Zhao Z, Shyr Y, Peek RM Jr.

Cancer Res. 2010 Jan 1;70(1):30-5. doi: 10.1158/0008-5472.CAN-09-2899.

34.

Matrix metalloproteinase-9 contributes to intestinal tumourigenesis in the adenomatous polyposis coli multiple intestinal neoplasia mouse.

Sinnamon MJ, Carter KJ, Fingleton B, Matrisian LM.

Int J Exp Pathol. 2008 Dec;89(6):466-75. doi: 10.1111/j.1365-2613.2008.00621.x.

35.

Establishment and quantitative imaging of a 3D lung organotypic model of mammary tumor outgrowth.

Martin MD, Fingleton B, Lynch CC, Wells S, McIntyre JO, Piston DW, Matrisian LM.

Clin Exp Metastasis. 2008;25(8):877-85. doi: 10.1007/s10585-008-9206-y. Epub 2008 Sep 12.

36.

Functional colonography of Min mice using dark lumen dynamic contrast-enhanced MRI.

Quarles CC, Lepage M, Gorden DL, Fingleton B, Yankeelov TE, Price RR, Matrisian LM, Gore JC, McIntyre JO.

Magn Reson Med. 2008 Sep;60(3):718-26. doi: 10.1002/mrm.21724.

37.

Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background.

Martin MD, Carter KJ, Jean-Philippe SR, Chang M, Mobashery S, Thiolloy S, Lynch CC, Matrisian LM, Fingleton B.

Cancer Res. 2008 Aug 1;68(15):6251-9. doi: 10.1158/0008-5472.CAN-08-0537.

38.

p120 and Kaiso regulate Helicobacter pylori-induced expression of matrix metalloproteinase-7.

Ogden SR, Wroblewski LE, Weydig C, Romero-Gallo J, O'Brien DP, Israel DA, Krishna US, Fingleton B, Reynolds AB, Wessler S, Peek RM Jr.

Mol Biol Cell. 2008 Oct;19(10):4110-21. doi: 10.1091/mbc.E08-03-0283. Epub 2008 Jul 23.

39.

Host nuclear factor-kappaB activation potentiates lung cancer metastasis.

Stathopoulos GT, Sherrill TP, Han W, Sadikot RT, Yull FE, Blackwell TS, Fingleton B.

Mol Cancer Res. 2008 Mar;6(3):364-71. doi: 10.1158/1541-7786.MCR-07-0309.

40.

A protective role of mast cells in intestinal tumorigenesis.

Sinnamon MJ, Carter KJ, Sims LP, Lafleur B, Fingleton B, Matrisian LM.

Carcinogenesis. 2008 Apr;29(4):880-6. doi: 10.1093/carcin/bgn040. Epub 2008 Feb 6.

PMID:
18258601
41.

Noninvasive detection of matrix metalloproteinase activity in vivo using a novel magnetic resonance imaging contrast agent with a solubility switch.

Lepage M, Dow WC, Melchior M, You Y, Fingleton B, Quarles CC, Pépin C, Gore JC, Matrisian LM, McIntyre JO.

Mol Imaging. 2007 Nov-Dec;6(6):393-403.

PMID:
18053410
42.

Use of bioluminescent imaging to investigate the role of nuclear factor-kappaBeta in experimental non-small cell lung cancer metastasis.

Stathopoulos GT, Sherrill TP, Han W, Sadikot RT, Polosukhin VV, Fingleton B, Yull FE, Blackwell TS.

Clin Exp Metastasis. 2008;25(1):43-51. Epub 2007 Nov 16.

PMID:
18008176
43.

Epithelial NF-kappaB activation promotes urethane-induced lung carcinogenesis.

Stathopoulos GT, Sherrill TP, Cheng DS, Scoggins RM, Han W, Polosukhin VV, Connelly L, Yull FE, Fingleton B, Blackwell TS.

Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18514-9. Epub 2007 Nov 13.

44.

Molecular targets in metastasis: lessons from genomic approaches.

Fingleton B.

Cancer Genomics Proteomics. 2007 May-Jun;4(3):211-21. Review.

45.

MMPs as therapeutic targets--still a viable option?

Fingleton B.

Semin Cell Dev Biol. 2008 Feb;19(1):61-8. Epub 2007 Jul 6. Review.

46.

Matrix metalloproteinase 7 mediates mammary epithelial cell tumorigenesis through the ErbB4 receptor.

Lynch CC, Vargo-Gogola T, Martin MD, Fingleton B, Crawford HC, Matrisian LM.

Cancer Res. 2007 Jul 15;67(14):6760-7.

47.

Loss of functional Fas ligand enhances intestinal tumorigenesis in the Min mouse model.

Fingleton B, Carter KJ, Matrisian LM.

Cancer Res. 2007 May 15;67(10):4800-6.

48.

Hu/Mu ProtIn oligonucleotide microarray: dual-species array for profiling protease and protease inhibitor gene expression in tumors and their microenvironment.

Schwartz DR, Moin K, Yao B, Matrisian LM, Coussens LM, Bugge TH, Fingleton B, Acuff HB, Sinnamon M, Nassar H, Platts AE, Krawetz SA, Linebaugh BE, Sloane BF.

Mol Cancer Res. 2007 May;5(5):443-54.

49.

Resident stromal cell-derived MMP-9 promotes the growth of colorectal metastases in the liver microenvironment.

Gorden DL, Fingleton B, Crawford HC, Jansen DE, Lepage M, Matrisian LM.

Int J Cancer. 2007 Aug 1;121(3):495-500.

50.

A rat monoclonal antibody that recognizes pro- and active MMP-7 indicates polarized expression in vivo.

Fingleton B, Powell WC, Crawford HC, Couchman JR, Matrisian LM.

Hybridoma (Larchmt). 2007 Feb;26(1):22-7.

Supplemental Content

Loading ...
Support Center